Close

BIO Thanks President Trump for Rejecting RIN Cap, Supporting E15

BIO thanked President Trump and Senators Charles Grassley (R-IA) and Joni Ernst (R-IA) for rejecting a price cap on Renewable Identification Numbers (RINs) and working to provide regulatory relief to enable year-round sales of E15.

BIO Launches New Report Profiling 100 Renewable Chemical Technology Companies

BIO's new “Renewable Chemical Platforms Building the Biobased Economy” report documents the rapid expansion of renewable chemical platforms and applications around the world, profiling 100 companies from 16 countries that are commercializing renewable chemical applications.

Wisconsin Governor Walker Signs Bill Facilitating Patient Access to Interchangeable Biologic Medicines

Washington, D.C. (April 10, 2018) – The Biotechnology Innovation Organization (BIO) and BioForward Wisconsin commend...

BIO Applauds Introduction of the Opioid Addiction Action Plan Act

Washington, DC (April 27, 2018) – BIO President and CEO Jim Greenwood issued the following statement regarding the Opioid Addiction Action Plan Act, introduced yesterday in the Senate by Senators Heller (R-NV), Isakson (R-GA), and Menendez (D-NJ). A companion bill in the House, sponsored by Representatives Yvette Clarke (D-NY) and Adam Kinzinger (R-IL), was advanced by the House Energy and Commerce Health Subcommittee earlier this week.

BIO Announces Gene Editing and Synthetic Biology Programming for 2018 World Congress

WASHINGTON, D.C. (April 26, 2018) – The Biotechnology Innovation Organization (BIO) today announced programming information for gene editing and synthetic biology at the 2018 World Congress on Industrial Biotechnology. Programming around these topics will kick off on Tuesday, July 17, with a plenary panel of experts to discuss how gene editing tools like CRISPR are revolutionizing the production of everyday products. Programming will continue with breakout sessions throughout the week, featuring executives from biotechnology companies, consumer goods producers and the government to explore the various applications for gene editing and synthetic biology in the field of industrial biotechnology.

Natural Alternatives International v. Creative Compounds (BIO Brief as Amicus Curiae)

Natural Alternatives International v. Creative Compounds (BIO Brief as Amicus Curiae supporting appellant in the US Court of Appeals for the Federal Circuit)

BIO Statement on Opioid Crisis Response Act of 2018

Washington, DC (April 24, 2018) – BIO President and CEO Jim Greenwood issued the following statement today regarding S. 2680, the Opioid Crisis Response Act of 2018:

BIO Submission to the China Section 301 Investigation - September 28, 2017

BIO submitted comments to the Office of the United States Trade Representative (USTR) and the inter-agency Section 301 Committee regarding the investigation, initiated on August 18, 2017,...

BIO Announces Keynote and Returns to Boston June 4-7 to Celebrate 25 Years of History-Making Innovation

TV's Robin Roberts will deliver the keynote address at the upcoming BIO International Convention which returns to Boston June 4-7. Celebrating its 25 year anniversary, BIO will host the event expected to attract more than 16,000 attendees and 1,800 exhibitors from 74 countries.

BIO Comments on FDA Draft Guidance Formal Meetings Between the Food and Drug Administration and Sponsors or Applicants of Prescription Drug User Fee Act Products

March 27, 2018

...